IDEXX Laboratories (IDXX), a diversified provider of diagnostic and information technology-based products and services for animal health and water testing, is identified as a top growth stock. The company holds a Zacks Rank #2 (Buy) and strong Style Scores, including a Growth Score of B and a VGM Score of B. Analysts project 17.6% year-over-year earnings growth for the current fiscal year, with the Zacks Consensus Estimate for fiscal 2025 recently increasing to $12.55 per share following two upward revisions, underscoring its potential for sustained performance.
IDEXX Laboratories (IDXX) is positioned as a top growth stock, evidenced by its Zacks Rank #2 (Buy) and strong Style Scores, including a Growth Score of B and a VGM Score of B. The company maintains a diversified presence in companion animal veterinary, livestock, water testing, and human point-of-care diagnostics markets. These robust fundamental ratings underscore its potential for sustained performance. The company exhibits significant financial momentum, with a forecasted year-over-year earnings growth of 17.6% for the current fiscal year. Analyst sentiment remains positive, as two analysts revised fiscal 2025 earnings estimates upwards in the last 60 days, increasing the Zacks Consensus Estimate to $12.55 per share. IDXX also consistently surpasses expectations, reporting an average earnings surprise of +6.1%. This combination of a high Zacks Rank and top-tier Growth and VGM Style Scores aligns with a strategy for identifying stocks with a high probability of market outperformance. The positive earnings estimate revisions further reinforce IDXX's attractive long-term growth profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
